Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an international AIDS society-USA panel

JAMA

Volumn 283, Issue 18, 2000, Pages 2417-2426

  Hirsch, Martin S ^a,m,n   Brun Vézinet, Françoise ^b   D'Aquila, Richard T ^a   Hammer, Scott M ^c   Johnson, Victoria A ^o   Kuritzkes, Daniel R ^d   Loveday, Clive ^e   Mellors, John W ^f   Clotet, Bonaventura ^g   Conway, Brian ^h   Demeter, Lisa M ⁱ   Vella, Stefano ^j   Jacobsen, Donna M ^k   Richman, Douglas D ^l  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BICHAT HOSPITAL   (France)

^c The New York Presbyterian Hospital   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ UNIVERSITY OF ROCHESTER   (United States)

^j ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^k International AIDS Society USA   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m Infectious Disease Unit   (United States)

ⁿ Box 29916   (United States)

^o NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG SCREENING; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHENOTYPE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0343183245     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.18.2417     Document Type: Article

References (94)

1. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA. 1998;279:1984-1991.
2. 3. Ann Intern Med. 1995;123:561-571.
3. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med. 1995;122: 401-408.
4. Japour AJ, Welles S, D'Aquila RT, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis. 1995;171:1172-1179.
5. Miller V, Phillips A, Rottmann C, et al. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy. J Infect Dis. 1998;177:1521-1532.
6. Harrigan PR, Montaner JS, Hogg RS, et al. Baseline resistance profile predicts response to ritonavir/ saquinavir therapy in a community setting. Antiviral Ther. 1998;3(suppl 1):38. Abstract 55.
7. Zolopa AR, Schafer RW, Warford A, et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med. 1999;131:813-821.
8. Deeks SG, Hellman NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen. J Infect Dis. 1999;179:1375-1381.
9. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS. 1999;13:F17-F21.
10. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy. Lancet. 1999; 353:2195-2199.
11. Clevenbergh P, Durant J, Halfon P, et al. Persisting long-term benefit of antiretroviral genotypic guided treatment for HIV-infected patients failing HAART. Antiviral Ther. 1999;4(suppl 1):42. Abstract 60.
12. Baxter JD, Mayers DL, Wentworth DN, et al. Final results of CPCRA 046: a pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Antiviral Ther. 1999;4(suppl 1): 43. Abstract 61.
13. Cohen C, Hunt S, Sension M, et al. Phenotypic resistance testing significantly improves response to therapy (Tx). From: 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 237.
14. Havlir DV, Hellman NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA. 2000;283:229-234.
15. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA. 2000;283:205-211.
16. De Pasquale MP, Murphy R, Kuritzkes D, et al. Resistance during early virological rebound on amprenavir plus zidovudine plus lamivudine triple therapy or amprenavir monotherapy in ACTC protocol 347. Antiviral Ther. 1998;3(suppl 1):50-51. Abstract 71.
17. Holder DJ, Condra J, Schleif WA, et al. Virologic failure during combination therapy with Crixivan and RT inhibitors is often associated with expression of resistance-associated mutations in RT only. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 492.
18. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000;44:920-928.
19. Vingerhoets J, Bloor S, Michiels L, et al. The accuracy and reproducibility of high throughput HIV-1 resistance testing under EN45001 and CLIA accreditation labels. Antiviral Ther. 1999;4(suppl 1):53. Abstract 77.
20. Gunthard HF, Wong JK, Ignacio CC, et al. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses. 1998;14:869-876.
21. Schuurman R, Brambilla D, de Groot T, et al. Second worldwide evaluation of HIV-1 drug resistance genotyping quality using the ENVA 2 panel. Antiviral Ther. 1999;4(suppl 1):41. Abstract 58.
22. Hertogs K, Bloor S, De Vroey V, et al. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother. 2000;44:568-573.
23. Larder B. New insights into genetic mechanisms of HIV drug resistance. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract S34.
24. Lanier R, Danehower S, Daluge S, et al. Genotypic and phenotypic correlates of response to abacavir (ABC, 1592). Antiviral Ther. 1998;3(suppl 1): 36. Abstract 52.
25. Coakley EP, Gillis JM, Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS. 2000;14:F9-F15.
26. Calvez V, Mouroux M, Yvon A, et al. Zidovudine resistance associated mutations can be selected in patients after long-term exposure to stavudine. Antiviral Ther. 1999;4(suppl 1):26. Abstract 38.
27. Pellegrin I, Izopet J, Reynes J, et al. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. AIDS. 1999;13:1705-1709.
28. Winters MA, Coolley KL, Girard YA, et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest. 1998;102:1769-1775.
29. Larder BA, Bloor S, Kemp SD, et al. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother. 1999;43:1961-1967.
30. Conway B. Development of drug resistance in patients receiving combinations of zidovudine, didanosine, and nevirapine. From: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy: September 26-29, 1999; San Francisco, Calif. Abstract 436.
31. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994;68:1660-1666.
32. Demeter LM, Shafer RW, Meehan PM, et al. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy. Antimicrob Agents Chemother. 2000;44:794-797.
33. Schuurman R, Demeter L, Reichelderfer P, et al. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol. 1999;37:2291-2296.
34. Hertogs K, Zolopa AR, Bloor S, et al. A blinded comparative analysis of two genotyping service laboratories. Antiviral Ther. 1999;4(suppl 1):59. Abstract 87.
35. Simon F, Loussert-Ajaka I, Damond F, et al. HIV type 1 diversity in northern Paris, France. AIDS Res Hum Retroviruses. 1996;12:1427-1433.
36. de Bethune MP, Hertogs K, Heyndrickx L, et al. Does natural or acquired resistance to reverse transcriptase and protease inhibitors, observed in HIV-1 groups M (subtypes A-H) and [O], differ from subtype B? Antiviral Ther. 1999;4(suppl 1):33. Abstract 49.
37. Casado JL, Hertogs K, Ruiz RL, et al. Rate of non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. Antiviral Ther. 1999;4 (suppl 1):78. Abstract 114.
38. Patick A, Zhang M, Hertogs K, et al. Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program. Antiviral Ther. 1998;3(suppl 1):39. Abstract 57.
39. Skowron G, Whitcomb J, Wesley M, et al. Viral load response to the addition of lamivudine correlates with phenotypic susceptibility to lamivudine and the presence of T215Y/F in the absence of M184V. Antiviral Ther. 1999;4(suppl 1):55. Abstract 81.
40. Miller MD, Wulfsohn MS, Margot NA, et al. Retrospective analysis of baseline susceptibility to adefovir dipivoxil is predictive of virological response in GS-96-408. Antiviral Ther. 1999;4(suppl 1):70. Abstract 106.
41. Hammer S, Demeter L, DeGruttola V, et al. Relationship of phenotypic and genotypic resistance profiles to virological outcome in a trial of abacavir, nelfinavir, efavirenz and adefovir dipivoxil in patients with virological failure receiving indinavir (ACTG 372). Antiviral Ther 1999;4(suppl 1):45 Abstract 64.
42. Call S, Westfall A, Cloud G, et al. Predictive value of HIV phenotypic susceptibility testing in a clinical cohort. From: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif Abstract LB-17.
43. Garraffo R, Durant J, Clevenbergh P, et al. Relevance of protease inhibitor plasma levels in patients treated with genotypic adapted therapy. Antiviral Ther. 1999;4(suppl 1):75. Abstract 109.
44. Verhofstede C, Van Wanzeele F, Van Der Gucht B, et al. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS. 1999;13:1541-1546.
45. Devereux HL, Youle M, Johnson MA, et al. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS. 1999;13:F123-F127.
46. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295-1300.
47. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278:1291-1295.
48. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995;269:696-699.
49. Nijhuis M, Schuurman R, de Jong D, et al. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis. 1997;176:398-405.
50. Kemp S, Shi C, Bloor S, et al. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine. J Virol. 1998;72:5093-5098.
51. Kuritzkes DR, Shugarts D, Bakhtiari M, et al. Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy. J Acquir Immune Defic Syndr. 2000;23:26-34.
52. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569-571.
53. Larder B, De Vroey V, Dehertogh P, et al. Predicting HIV-1 phenotypic resistance from genotype using a large phenotype-genotype relational database. Antiviral Ther. 1999;4(suppl 1):41. Abstract 59.
54. Acosta EP, Havlir DV, Richman DD, et al. Pharmacodynamics (PD) of indinavir (IDV) in protease-naive HIV-infected patients receiving ZDV and 3TC. From: 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 455.
55. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-294.
56. Schuetz JD, Connelly MC, Sun D, et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med. 1999;5:1048-1051.
57. Martinez-Picado J, Savara AV, Sutton L, et al. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol. 1999; 73:3744-3752.
58. Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 1998;37:3594-3601.
59. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307-311.
60. Yerly S, Kaiser L, Race E, et al. Reverse transcriptase and protease gene analysis at the time of primary HIV-1 infection. Antiviral Ther. 1998;3(suppl 1): 75. Abstract 107.
61. Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection, JAMA 1999;282:1142-1149.
62. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999; 282:1135-1141.
63. Alexander C, Dong W, Mo T, et al. Primary antiretroviral resistance in recently infected injection drug users and in drug naive individuals. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 5, 1999; Chicago, Ill. Abstract 218.
64. Verhelst R, Verhofstede C, Van Der Gucht B, et al. Prevalence of drug-resistance mutations in the HIV-1 reverse transcriptase and protease region in previously untreated patients from Belgium. Antiviral Ther. 1998;3(suppl 1):78-79. Abstract 113.
65. Brodine SK, Shaffer RA, Starkey MJ, et al. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med. 1999;131:502-506.
66. Wegner S, Brodine S, Mascola J, et al. High frequency of antiretroviral drug resistance in HIV-1 from recently infected therapy-naive individuals. Antiviral Ther. 1999;4(suppl 1):85. Abstract 119.
67. Bacheler LT, Jeffrey S, Cordova B, et al. Baseline prevalence of mutations linked to non-nucleoside reverse transcriptase inhibitor resistance in patients enrolled in clinical studies of efavirenz. Antiviral Ther. 1999;4(suppl 1):63. Abstract 94.
68. Conway B, Montessori V, Rouleau D, et al. Primary lamivudine resistance in acute/early human immunodeficiency virus infection. Clin Infect Dis. 1999; 28:910-911.
69. Salomon H, Wainberg MA, Brenner B, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS. 2000;14:F17-F23.
70. Williams IG, Kaye S, Williams DI, et al. Antiretroviral drug-resistant genotypic mutations in HIV-infected persons at first diagnosis (1988-1997). Antiviral Ther. 1998;3(suppl 1):80. Abstract 116.
71. Riva C, Berlusconi A, Violin M, et al. Prevalence of drug-resistant HIV-1 variants of RT region and natural polymorphism in protease coding region of recently infected individuals. Antiviral Ther. 1998;3 (suppl 1):81. Abstract 117.
72. Gomez-Cano M, Rubio A, Puig T, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS. 1998; 12:1015-1020.
73. Soriano V, Clotet B, Leal M, et al. Prevalence of genotypic resistance to nucleoside analogues in Spain (June 1998). Antiviral Ther. 1998;3(suppl 5):24-25. Abstract 18A.
74. Fontaine E, Hemmer F, Plesseria JM, et al. Drug resistance mutations in HIV-1 strains from treatment-naive patients (Luxembourg 1992-1997). From: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 42199.
75. Sabino EC, Saéz-Alquezar A, Barreto CC. Prevalence of mutations that confer resistance to RT inhibitors among drug naive HIV-positive blood donors in Sāo Paulo/Brazil. From: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 11168.
76. Garcia Lerma JG, Weinstock H, Stang H, et al. Identification and characterization of a novel multidrug resistance mutation (Q151L) in drug-naive HIV-1 seroconverters. Antiviral Ther. 1998;3(suppl 1):85. Abstract 123.
77. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997; 337:734-739.
78. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989;243:1731-1734.
79. + T cell responses associated with control of viremia. Science. 1997;278: 1447-1450.
80. Musey LK, Krieger JN, Hughes JP, et al. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis. 1999;180:278-284.
81. Verbiest W, Schel P, Conant M, et al. An epidemiological prospective survey assessing the prevalence of HIV-1 drug resistance in 230 HIV-1-positive antiretroviral-naive patients from the USA. Antiviral Ther. 1999;4(suppl 1):86-87. Abstract 122.
82. Descamps D, Costagliola D, Glaude G, et al. Prevalence of resistance mutations in antiretroviral-naive patients. Antiviral Ther. 1999;4(suppl 1):87. Abstract 123.
83. Harrigan PR, Alexander C, Dong W, et al. Prevalence of resistance-associated mutations in patients starting antivirals. Antiviral Ther. 1999;4(suppl 1): 88. Abstract 124.
84. Deeks SG, Wrin T, Hoh R, et al. Virologic and immunologic evaluation of structured treatment interruptions (STI) in patients experiencing long-term virologic failure. From: 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract LB10.
85. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. JAMA. 1998;280:78-86.
86. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults. JAMA. 2000;283:381-390.
87. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy. AIDS. 1998;12:1619-1624.
88. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. J Infect Dis. 1999;180:99-105.
89. Centers for Disease Control and Prevention. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep. 1998;47(RR-2):1-30.
90. US Department of Health and Human Services and the Henry J Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-inferted adults and adolescents. Available at: http://www.hivatis.org/ trtgdlns.html. Accessed January 28, 2000.
91. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 1996;335: 1621-1629.
92. Becker-Pergola G, Guay L, Mmiro F, et al. Selection of the K103 nevirapine (NVP) resistance mutation in Ugandan women receiving NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET-006). From: 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 658.
93. Johnson VA, Woods C, Hamilton CD, et al. Vertical transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 266.
94. Chaix C, Grenier-Sennelier C, Durant J, et al. Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the Viradapt study. Antiviral Ther. 1999;4(suppl 1): 69-70. Abstract 105.